Newsletter Signup | Join Community
Ocular melanoma is an uncommon cancer of the eye requiring aggressive treatment by specialized physicians.
FDA grants "Breakthrough Therapy Designation" for Bempegaldesleukin + Opdivo for previously untreated advanced Melanoma
Genomic testing should be performed in all patients-precision medicines reduce recurrences and prolong survival.
Keytruda immunotherapy + BRAF- MEK Inhibitors combo further delays melanoma progression compared BRAF-MEK alone.
Keytruda treatment for melanoma improves survival, treats CNS disease and may be most effective when used in combination
BRAF-MEK combination improves survival in stage III and advanced melanoma with V600E and V600K mutations
Opdivo anti-PD-1 immunotherapy can be used to treat both stage III and more advanced melanoma.
Anyone have experience with TVEC? Looking to learn from others. Thanks
A new very active treatment option for Melaoma-Braftovihttps://mavendoctors…